Company: FTII
Filing Date: 2025-04-09
Form Type: 10-K
Source: 0001641172-25-003384
Chunk: 239

Company: FutureTech II Acquisition Corp.
Filing Date: 2025-04-09
Form: 10-K
Item: Item 11
Chunk 239
---
 would be February 14, 2025. If the Company is unable to complete an initial
business combination by February 14, 2025 and seeks to extend beyond such 36-month period, such extension would violate Nasdaq IM-5101-2.
Effective on October 7, 2024, Nasdaq Rule 5815 was amended to provide for the immediate suspension and delisting upon issuance of a delisting
determination letter to an issuer for failure to meet the requirements of Nasdaq IM5101-02. Accordingly, because the Company could not
consummate an initial business combination by February 14, 2025, on February 19, 2025, the Company received a notice from the Nasdaq
stating that the Company did not comply with Nasdaq Interpretive Material IM-5101-2, and that trading of the Company’s securities
on Nasdaq would be suspended at the opening of business on February 26, 2025, and a Form 25-NSE will be filed with the SEC which will
remove the Company’s securities from listing on Nasdaq. The Company did not appeal Nasdaq’s determination to delist the Company
securities and accordingly, the Company’s securities was suspended from trading on Nasdaq at the opening of business on February
26, 2025. On February 25, 2025, the Company received a letter of approval from FINRA to begin trading over the counter with the symbols
“FTII” “FTIIU” and “FTIIW” commencing on February 26, 2025. The Company expects that Nasdaq will
file a Form 25-NSE with the SEC to delist its securities, and that the delisting will become effective ten (10) days after Nasdaq files
the Form 25 with the SEC to complete the delisting. The Company does not intend to file a Form 15 with the SEC to terminate the registration
of its securities under the Securities Exchange Act of 1934, as amended, and expects that the Company’s securities will be quoted
on the over-the-counter market.

If
this were to occur, we could face significant material adverse consequences, including our ability to consummate the Business Combination;
reduced liquidity for our securities; a limited availability of market quotations for our securities; a determination that our shares
of common stock are a “penny stock” which will require brokers trading in our shares of common stock to adhere to more stringent
rules